More articles from Cancer Diagnosis and Management

  • The rationale for, and design of, a lung cancer screening program

    Peter Mazzone, MD, MPH
    • Cleveland Clinic Journal of Medicine May 2012, 79 (5) 337-345;
    • DOI: https://doi.org/10.3949/ccjm.79a.12018

    • We are entering a new era in which lung cancer screening may be considered the standard of care.

  • Managing cancer pain: Frequently asked questions

    Raghava R. Induru, MD and Ruth L. Lagman, MD, MPH, FACP
    • Cleveland Clinic Journal of Medicine July 2011, 78 (7) 449-464;
    • DOI: https://doi.org/10.3949/ccjm.78a.10054

    • Cancer pain: its pathogenesis, how to assess it, and how to treat it—in particular, how to use opioids optimally.

  • TOC Icon

    A practical guide to prostate cancer diagnosis and management

    Matthew N. Simmons, MD, PhD, Ryan K. Berglund, MD and J. Stephen Jones, MD
    • Cleveland Clinic Journal of Medicine May 2011, 78 (5) 321-331;
    • DOI: https://doi.org/10.3949/ccjm.78a.10104

    • Screening, diagnosis, and management of prostate cancer can be complicated, with no clear consensus about key issues. Our approach refl ects the guidelines from the American Urological Association.

  • Malignant bowel obstruction: Individualized treatment near the end of life

    Aileen Soriano, MD and Mellar P. Davis, MD
    • Cleveland Clinic Journal of Medicine March 2011, 78 (3) 197-206;
    • DOI: https://doi.org/10.3949/ccjm.78a.10052

    • Surgery should not be routinely done. Less-invasive approaches such as gastric and colonic stenting are useful.

  • Symptom management: An important part of cancer care

    Laura K. Shoemaker, DO, Bassam Estfan, MD, Raghava Induru, MD and T. Declan Walsh, MD
    • Cleveland Clinic Journal of Medicine January 2011, 78 (1) 25-34;
    • DOI: https://doi.org/10.3949/ccjm.78a.10053

    • In addition to diagnosing and managing the cancer itself, the physician’s duty is also to recognize and effectively manage the many associated symptoms.

  • Prostate-specific antigen: How to advise patients as the screening debate continues

    Peter C. Albertsen, MD, MS
    • Cleveland Clinic Journal of Medicine June 2005, 72 (6) 521-527;

    • There is still no consensus on whether prostate-specific antigen measurement should be used as a screening test for prostate cancer, but patients have the right to be informed about its risks and possible benefits.

  • Cancer pain: How to measure the fifth vital sign

    Mellar P. Davis, MD and Declan Walsh, MSc
    • Cleveland Clinic Journal of Medicine August 2004, 71 (8) 625-632;

    • To control pain effectively in cancer patients, we must assess it regularly and consistently.

  • Progress in preventing chemotherapy-induced nausea and vomiting

    Maurie Markman, MD
    • Cleveland Clinic Journal of Medicine August 2002, 69 (8) 609-617;

    • Our understanding of the pathophysiology of emesis has improved, and we now have drugs that can prevent acute emesis in most patients. Delayed and anticipatory emesis remain a challenge.

  • Malignant melanoma: Treatments emerging, but early detection is still key

    Maurie Markman, MD, Paul Masci, DO and Ernest C. Borden, MD
    • Cleveland Clinic Journal of Medicine July 2002, 69 (7) 529-545;

    • Interferon alfa-2b can increase disease-free survival in malignant melanoma, but we can have far more impact by detecting this disease earlier and by teaching patients how to recognize and possibly avoid it.

  • Assessing cancer clinical trials: Will your patient benefit from a ‘breakthrough’?

    Maurie Markman, MD
    • Cleveland Clinic Journal of Medicine May 2002, 69 (5) 368-376;

    • Pick up a newspaper or turn on the news, and you will see a story about some breakthrough in cancer. So will your patients.

Previous
Next